Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on August 5, 2009
Japanese Journal of Clinical Oncology 2009 39(11):767-770; doi:10.1093/jjco/hyp081
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
39/11/767    most recent
hyp081v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Kondo, M.
Right arrow Articles by Toi, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kondo, M.
Right arrow Articles by Toi, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Author (2009). Published by Oxford University Press. All rights reserved

Budget Impact Analysis of Chemoprevention of Breast Cancer with Tamoxifen and Raloxifene among High-risk Women in Japan

Masahide Kondo1,2, Shu-Ling Hoshi1 and Masakazu Toi3

1 Department of Health Care Policy and Management, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki
2 Clinical Research Division, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Bunkyo-ku, Tokyo
3 Department of Surgery, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto, Japan

For reprints and all correspondence: Masahide Kondo, Department of Health Care Policy and Management, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki 305-8577, Japan. E-mail: mkondo{at}md.tsukuba.ac.jp

Received May 13, 2009; accepted June 23, 2009

‘Cost saving’ was suggested in our recent economic evaluation of chemoprevention of breast cancer targeting women at high risk in Japan. However, this budget impact analysis reveals that the introduction of chemoprevention appears to be not budget saving for ~20 years, whereas the level of budget impact seems affordable.

Key Words: breast cancer • budget • chemoprevention • raloxifene • tamoxifen


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.